NAMPT and breast cancer: Paradoxically, Antonio F. Santidrian etal. reported that knockdown of visfatin, the enzyme catalyzing the rate-limiting step of the NAD+ salvage pathway, enhanced metastatic aggressiveness in human breast cancer cells [25].